Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Fleischmann

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
Cardiovascular Research|January 1, 2000
The 2.3 kb smooth muscle myosin heavy chain promoter directs gene expression into the vascular system of transgenic mice and rabbitsW M Franz, O J Mueller, M Fleischmann, et al.
The Journal of Rheumatology. Supplement|February 6, 2009
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidenceStanley B Cohen, Marc D Cohen, John J Cush, et al.
The Journal of Rheumatology|April 3, 2003
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial resultsRoy M Fleischmann, Scott W Baumgartner, Elizabeth A Tindall, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Rheumatology and Therapy|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Arthritis and Rheumatism|June 10, 2003
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observationsJoel M Kremer, Michael E Weinblatt, Arthur D Bankhurst, et al.
The New England Journal of Medicine|January 28, 1999
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateM E Weinblatt, J M Kremer, A D Bankhurst, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid ArthritisRoy M Fleischmann, Frank Wagner, Alan J Kivitz, et al.
Annals of the Rheumatic Diseases|December 4, 2013
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trialTom W J Huizinga, Roy M Fleischmann, Martine Jasson, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trialWilliam Stohl, Juan Gomez-Reino, Ewa Olech, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Cardiovascular Research|January 1, 2000
The 2.3 kb smooth muscle myosin heavy chain promoter directs gene expression into the vascular system of transgenic mice and rabbitsW M Franz, O J Mueller, M Fleischmann, et al.
The Journal of Rheumatology. Supplement|February 6, 2009
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidenceStanley B Cohen, Marc D Cohen, John J Cush, et al.
The Journal of Rheumatology|April 3, 2003
Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial resultsRoy M Fleischmann, Scott W Baumgartner, Elizabeth A Tindall, et al.
Annals of the Rheumatic Diseases|November 9, 2012
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patientsRonald F van Vollenhoven, Paul Emery, Clifton O Bingham, et al.
Rheumatology and Therapy|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials)Roy M Fleischmann, Vibeke Strand, Eugen Feist, et al.
Arthritis and Rheumatism|June 10, 2003
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observationsJoel M Kremer, Michael E Weinblatt, Arthur D Bankhurst, et al.
The New England Journal of Medicine|January 28, 1999
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexateM E Weinblatt, J M Kremer, A D Bankhurst, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid ArthritisRoy M Fleischmann, Frank Wagner, Alan J Kivitz, et al.
Annals of the Rheumatic Diseases|December 4, 2013
Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trialTom W J Huizinga, Roy M Fleischmann, Martine Jasson, et al.
Annals of the Rheumatic Diseases|February 7, 2012
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trialWilliam Stohl, Juan Gomez-Reino, Ewa Olech, et al.
Pageof 16